In March of 2019, the S(+) stereoisomer of ketamine named esketamine was approved from the FDA as a quick-performing antidepressant. It relieves the signs and symptoms of depression in four several hours of use and these results can very last for as long as several weeks.With scientific evidence exhibiting us copyright in the Mind, what can we conc… Read More